Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR‐T Therapy
If confirmed in a large patient cohort, these findings could form the basis for modifying current patient selection criteria. Consistently negative patients may be suboptimal candidates for anti-CD19 CAR-T therapy. Alternative therapeutic options, such as bispecific antibodies or polatuzumab-based regimens, could be considered for this subset of patients.
Authors
- Ana Benzaquén (ORCID: https://orcid.org/0000-0003-4015-0831)
- Blanca Ferrer Lores (ORCID: https://orcid.org/0000-0001-9452-7310)
- Alicia Serrano (ORCID: https://orcid.org/0000-0002-6936-3913)
- Rosa Goterris (ORCID: https://orcid.org/0000-0003-0476-9696)
- Anabel Teruel (ORCID: https://orcid.org/0000-0003-1559-7607)
- María José Remigia
- Antonio Ferrández‐Izquierdo
- Begoña Heras (ORCID: https://orcid.org/0000-0003-3469-7988)
- Ignacio Arroyo
- Paula Amat (ORCID: https://orcid.org/0000-0001-6321-4952)
- Rafael Hernani (ORCID: https://orcid.org/0000-0003-1043-8076)
- José Luís Piñana (ORCID: https://orcid.org/0000-0001-8533-2562)
- Irene Pastor‐Galán (ORCID: https://orcid.org/0000-0002-3872-2151)
- María José Terol (ORCID: https://orcid.org/0000-0002-9467-932X)
- Ana Saus
- Juan Carlos Hernández‐Boluda (ORCID: https://orcid.org/0000-0002-4289-3113)
- Carlos Solano (ORCID: https://orcid.org/0000-0003-3702-0817)
- Laura Ventura (ORCID: https://orcid.org/0000-0001-7322-998X)
- Carolina Martínez‐Ciarpaglini (ORCID: https://orcid.org/0000-0002-8797-2114)
- Marcos Rivada
- Consejo Ortí
- Ariadna Pérez (ORCID: https://orcid.org/0000-0003-3596-2130)
- Montse Gómez
Institutions
- Universitat de València (ES)
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- eJHaem
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1002/jha2.70015
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05